Key result
Systemic treatment with cyclophosphamide, vincristine, and dacarbazine (CVD) achieved a partial remission and symptomatic relief in a patient with metastatic carotid body tumor.
Why the study?
Carotid body tumors rarely metastasize, with few metastatic cases reporting detailed systemic therapy and no conclusive consensus on effective management.
Does CVD chemotherapy improve tumor response and symptoms in patients with metastatic carotid body tumors?
Case Report (n=1)
Does CVD chemotherapy improve tumor response and symptoms in patients with metastatic carotid body tumors?
Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD) may be an effective systemic treatment for metastatic carotid body tumors, achieving partial remission and symptom relief.
May offer palliative benefit in metastatic carotid body tumors; hypothesis-generating and should not yet change practice.
RATIONALE: Carotid body tumors (CBTs) are head and neck paragangliomas (PGLs) with a low incidence of distant metastasis. To date, only a few metastatic cases treated with detailed systemic therapy are reported and effective management is still inconclusive. Herein, we reported a metastatic CBT case with systemic therapy and reviewed the reported systemic treatment. PATIENT CONCERNS: A 56-year-old man noticed multiple painless nodules on the right side of the neck and developed debilitating chest and back pain 7 years after the CBT resection. DIAGNOSES: Widespread bone and lymph nodes CBT metastases. INTERVENTIONS: Biopsies of the enlarged lymph nodes confirmed the diagnosis of metastatic CBT and 18F-FDG PET-CT detected multiple right cervical lymph nodes and bone metastases. 24 cycles of cyclophosphamide, vincristine and dacarbazine (CVD) chemotherapy were given since May 2016 to Jul 2018 and dacarbazine maintenance therapy was given in the next 15 months follow-up period. OUTCOMES: Partial remission was achieved according to the Response Evaluation in Criteria in Solid Tumors 1.1 criteria. A prominent control in the metastatic lesions were also observed in 18F-FDG PET-CT scan. LESSONS: Evidence for systemic management of metastatic CBTs is mainly based on studies of PGLs and pheochromocytoma. According to our review on metastatic CBT cases treated with systemic therapy from 1981 to 2018, chemotherapy, especially the CVD regimen, was a common reported management. In SDHB mutated patients, sunitinib and temozolomide could also be considered.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2020) conducted a case report in Metastatic carotid body tumor (n=1). Cyclophosphamide, vincristine, and dacarbazine (CVD) was evaluated on Radiologic response according to RECIST 1.1 criteria. Systemic treatment with cyclophosphamide, vincristine, and dacarbazine (CVD) achieved a partial remission and symptomatic relief in a patient with metastatic carotid body tumor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: